Early Options - A Provider's Guide to Medical Abortion Early Options - A Provider's Guide to Medical Abortion Early Options - A Provider's Guide to Medical Abortion
Home
Information About the Early Options Program
CME Information
Women's Experiences: Video Clips
Video Help
Back to prochoice.org
National Abortion Federation
References - Counseling for Medical Abortion
  1. Picker Institute. From the Patient's Perspective: Quality of Abortion Care [survey]. Menlo Park, Calif: Henry J Kaiser Family Foundation; 1999.
     
  2. Winikoff B, Sivin I, Coyaji KJ, et al. Safety, efficacy, and acceptability of medical abortion in China, Cuba, and India: a comparative trial of mifepristone-misoprostol versus surgical abortion. Am J Obstet Gynecol. 1997;176:431-437.
     
  3. Henshaw RC, Naji SA, Russell IT, Templeton AA. Comparison of medical abortion with surgical vacuum aspiration: women's preferences and acceptability of treatment. Br Med J. 1993;307:714-717.
     
  4. Lichtenberg ES, Grimes DA, Paul M. Abortion complications: prevention and management. In: Paul M, Lichtenberg ES, Borgatta L, Grimes DA, Stubblefield PG, eds. A Clinician's Guide to Medical and Surgical Abortion. New York, NY: Churchill Livingstone; 1999:197-216.
     
  5. Wiebe ER. Choosing between surgical abortions and medical abortions induced with methotrexate and misoprostol. Contraception. 1997;55:65-71.
     
  6. Planned Parenthood of New York City. Counseling Guide for Clinicians Offering Medical Abortion. New York, NY: Planned Parenthood of New York City; 1996.
     
  7. Harvey SM, Blackman LJ, Satre SJ. Listening to and Learning from Health Care Providers about Methotrexate-Induced Abortions: A Report of the Pacific Institute. Los Angeles, Calif: Pacific Institute for Women's Health; 1999.
     
  8. Joffe C. Reactions to medical abortion among providers of surgical abortion: an early snapshot. Fam Plann Perspect. 1999;31:35-38.
     
  9. Creinin MD, Burke AE. Methotrexate and misoprostol for early abortion: a multicenter trial. Contraception. 1996;54:19-22.
     
  10. Harvey SM, Beckman LJ, Castle MA, Coeytaux F. Knowledge and perceptions of medical abortion among potential users. Fam Plann Perspect. 1995;27(5):203-207.
     
  11. Goldberg AB, Greenberg MB, Darney PD. Misoprostol and pregnancy. N Engl J Med 2001;344:38-47.
     
  12. Kahn JG, Becker BS, MacIsaac L, et al. The efficacy of medical abortion: a meta-analysis. Contraception. 2000;61:29-40.
     
  13. Creinin MD, Aubény E. Medical abortion in early pregnancy. In: Paul M, Lichtenberg ES, Borgatta L, Grimes DA, Stubblefield PG, eds. A Clinician's Guide to Medical and Surgical Abortion. New York, NY: Churchill Livingstone; 1999:99-106.
     
  14. Danielsson KG, Marions L, Rodriguez A, Spur BW, Wong PYK, Bygdeman M. Comparison between oral and vaginal administration of misoprostol on uterine contractility. Obstet Gynecol. 1999;93:275-280.
     
  15. Meckstroth KR, Darney PD. Prostaglandins for first-trimester termination. Best Pract Res Clin Obstet Gynaecol 2003;17:745-63.
     
  16. Spitz IM, Bardin CW, Benton L, Robbins A. Early pregnancy with mifepristone and misoprostol in the United States. N Engl J Med. 1998;338:1241-1247.
     
  17. Creinin MD, Spitz IM. Use of various ultrasonographic criteria to evaluate the efficacy of mifepristone and misoprostol for medical abortion. Am J Obstet Gynecol. 1999;181:1419-1424.
     
  18. Peyron R, Aubény E, Targosz V, et al. Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. N Engl J Med. 1993;328:1509-1513.
     
  19. Aubény E, Peyron R, Turpin CL, et al. Termination of early pregnancy (up to 63 days of amenorrhea) with mifepristone and increasing doses of misoprostol. Int J Fertil Menopausal Stud. 1995;40(suppl):85-91.
     
  20. Newhall EP, Winikoff B. Abortion with mifepristone and misoprostol: regimens, efficacy, acceptability and future directions. Am J Obstet Gynecol. 2000;183(2)(suppl):S44-S53.
     
  21. Allen RH,Westhoff C, De Nonno L, Fielding SL, Schaff EA. Curettage after mifepristone-induced abortion: frequency, timing, and indications. Obstet Gynecol 2001;98:101-106.
     
  22. Harper C, Winikoff B, Ellertson C, Coyaji K. Blood loss with mifepristone-misoprostol abortion: measures from a trial in China, Cuba, and India. Int J Gynecol Obstet. 1998;63:39-49.
     
  23. Schaff EA, Eisinger SH, Stadalius LS, Franks P, Gore BZ, Poppema S. Low-dose mifepristone 200 mg and vaginal misoprostol for abortion. Contraception. 1999;59:1-6.
     
  24. Creinin MD, Vittinghoff E, Schaff EA, Klaisle C, Darney PD, Dean C. Medical abortion with oral methotrexate and vaginal misoprostol. Obstet Gynecol. 1997;90:611-616.
     
  25. Schaff EA, Stadalius LS, Eisinger SH, Franks P. Vaginal misoprostol administered at home after mifepristone (RU 486) for abortion. J Fam Pract. 1997;44:353-360.
     
  26. Creinin MD. Medical abortion with methotrexate 75 mg intramuscularly and vaginal misoprostol. Contraception. 1997;56:367-371.
     
  27. Kruse B, Poppema S, Creinin MD, Paul M. Management of side effects and complications in medical abortion. Am J Obstet Gynecol. 2000;183(2)(suppl):S65-S75.
     
  28. Mifeprex® product labeling - revised July 19, 2005. Available at http://www.fda.gov/cder/drug/infopage/mifepristone/
     
  29. FDA. FDA Public Health Advisory: Sepsis and Medical Abortion Update March 17, 2006 www.fda.gov/cder/drug/advisory/mifeprex200603.htm
     
  30. Centers for Disease Control and Prevention, US Food and Drug Administration, and the National Institute of Allergy and Infectious Diseases. Meeting transcript for the Public Workshop on Emerging Clostridial Disease (Atlanta).11 May 2006. Available at: www.fda.gov/cder/meeting/clostridial/transcript.pdf. Accessed May 23, 2007
     
  31. Breitbart V. Counseling for medical abortion. Am J Obstet Gynecol. 2000;183(2)(suppl):S26-S33.

 
Click here to return to Module 3 - Counseling for Medical Abortion.

©2005 Copyright National Abortion Federation
Disclaimer | Contact Us